Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a phase 2 trial.
Oliver DorigoAmit M OzaTanja PejovicPrafull GhatageSharad A GhamandeDiane ProvencherLisa D MacDonaldHeather L TorreyValarmathy KaliaperumalWalead EbrahimizadehHeather A HirschYogesh BramhechaJeannine VillellaStephan FisetPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
MVP-S with intermittent low-dose CPA is well-tolerated, with clinical benefit for patients with recurrent OvCa. Observed responses are irrespective of the platinum status.